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Abstract 
Background: Tuberculosis (TB) remains a major public health concern worldwide. Previous studies have demon-
strated that IL-17 plays an important role in initial immune response and is involved in both immune-mediated pro-
tection and pathology following infection with Mycobacterium tuberculosis (MTB). However, the alterations and regula-
tion of plasma IL-17 level during TB treatment remain unclear. Moreover, the cell type responsible for the production 
of IL-17 in TB patients requires further study.
Methods: A total of 20 acid-fast bacilli smear-positive (AFB-positive) pulmonary TB patients and 20 age- and gender-
matched healthy volunteers were included in our study. Blood samples were collected in heparinized tubes at the 
time of diagnosis (AFB-positive group) and 3 weeks after the initiation of therapy, when the sputum smear conver-
sion (AFB-negative group) occurred, followed by symptomatic improvement. IL-17 levels and IL-17-producing cells in 
PBMCs were detected. Lymphocyte populations in the peripheral blood between the AFB-positive and AFB-negative 
groups were compared by flow-cytometry. A549 cells, a cell line of alveolar epithelial cells, were applied to determine 
the extent of the pathological damage mediated by IL-17 following MTB infection. Recombinant human IL-10 was 
used to investigate the regulation of IL-17 expression after sputum smear conversion in AFB-positive pulmonary TB 
patients.
Results: Plasma IL-17 level were elevated in patients with sputum AFB-positive pulmonary TB, but substantially 
decreased after TB treatment and smear conversion. Our data indicate that NKT-like cells might be the main source of 
IL-17, in addition to conventional T cells in AFB-positive pulmonary TB patients. The secretion of IL-17 may be sup-
pressed by regulatory T (Treg) cells and IL-10 during TB treatment. Moreover, the IL-17 levels were positively correlated 
to both the C-reactive protein and erythrocyte sedimentation rate. Therefore, IL-17 was capable of alveolar epithelial 
cell damage following MTB infection.
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Background
Tuberculosis (TB) is a communicable respiratory disease 
caused by infection with Mycobacterium tuberculosis 
(MTB), and ranks as the second leading cause of death 
from the infectious diseases worldwide [1]. In 2013, there 
were 9  million new cases of TB diagnosed and 1.5  mil-
lion deaths due to the disease [1]. Adaptive immune 
responses mediated by CD4+ T cells and CD8+ T cells, 
and T helper (Th) 1 cytokines characterized by inter-
feron (IFN)-γ production are associated with a good 
prognosis and play an important role in countering the 
progression of MTB infection [2–4]. However, Th1 cells 
(primarily CD4+ cells producing IFN-γ) alone are not 
capable of controlling the infection [3, 5] and other fac-
tors, including Th2 cells, Th17 cells and regulatory T cells 
(Treg cells), are also involved in the progression of MTB 
infection.
Interleukin (IL)-17, also known as IL-17A, is a num-
ber of the IL-17 family which range from A to F [6, 7]. 
However, IL-17 is of particular importance as it is the 
cytokine primarily secreted by Th17 cells [6, 7]. IL-17 
production can be efficiently induced from naive CD4+ 
T cell by the IL-23 or IL-6, independently of TGF-β [8]. 
Recent studies have shown that IL-17 plays an important 
role in the initial immune responses and is involved in 
both immune protection and immune pathology in MTB 
infection [2, 9, 10]. The Th17-response is also considered 
to be the leading mechanism of protection of bronchoal-
veolar tract and its barrier maintenance [11].
IL-17 producing CD4+ T cells, activated in response to 
vaccination, has been shown to inhibit bacterial growth 
in the lung after MTB infection, as well as promote the 
production of chemokines that recruit and activate neu-
trophils and IFN-γ producing CD4+ T cells [12–15]. 
Moreover, IL-17 is essential for the vaccine-induced pro-
tection against MTB infection by inducing the localiza-
tion of the proinflammatory cytokine producing C-X-C 
motif chemokine receptor 5-positive (CXCR5+) T cells, 
thereby promoting early macrophage activation and the 
control of MTB [16]. In contrast, other studies demon-
strated that IL-17 played an essential role in granuloma 
formation  in  the  lung [17], and was involved in the 
pathological damage mediated by the initial neutrophil 
recruitment following MTB infection [18]. To limit this 
pathological damage, a serial of immune regulatory fac-
tors are in place, including regulatory T (Treg) cells and 
the production of the anti-inflammatory cytokine IL-10 
[19, 20]. IL-10 production by Tregs can effectively inhibit 
not only IFN-γ expression but also the ability of CD4+ 
T cells and CD8+ T cells to degranulate in response to 
MTB [19]. However, the dynamic changes and regulation 
of IL-17 during TB treatment remains unclear. Moreo-
ver, the cell type that is the primary source of IL-17 in TB 
patients has not been identified to date.
Here, we recruited patients with sputum acid-fast 
bacilli smear-positive (AFB-positive) pulmonary TB, and 
compared the changes of plasma cytokines before the 
initiation of anti-TB therapy and after the sputum smear 
conversion. We found that plasma IL-17 was elevated in 
the AFB-positive patients, but substantially decreased 
following TB treatment and smear conversion. Moreover, 
IL-17 levels were positively correlated to both the C-reac-
tive protein (CRP) and erythrocyte sedimentation rate 
(ESR). IL-17 also aggravated alveolar epithelial cells dam-
age following MTB infection. Our findings further indi-
cate that NKT-like cells might also be the main source of 
IL-17, in addition to conventional T cells in TB patients. 
Moreover, the secretion of IL-17 may be regulated by 
Treg cells and IL-10 during anti-TB treatment.
Methods
Patients and associated procedures
A total of 20 AFB-positive pulmonary TB patients and 
20 age- and gender-matched healthy volunteers were 
recruited at the First Affiliated Hospital, School of Medi-
cine, Zhejiang University from June 2014 to Novem-
ber 2014. All TB patients were diagnosed according to 
China’s  TB diagnosis standard. Any patients that were 
co-infected with other pathogens or had autoimmune 
diseases were excluded from this study. Written informed 
consent was obtained from all patients and healthy vol-
unteers. The study protocol was approved by the Eth-
ics committee of the First Affiliated Hospital, School of 
Medicine, Zhejiang University (reference number 2015-
312). The clinical characteristics for all of the study par-
ticipants are presented in Table 1.
Sample collection
Blood samples were collected in heparinized tubes at 
the time of diagnosis (AFB-positive group) and 3 weeks 
after the initiation of therapy when the sputum smear 
conversion (AFB-negative group) occurred, followed by 
Conclusion: The increase in the frequency of Treg cells and IL-10 levels was associated with a decrease in IL-17 in 
patients receiving TB treatment. Thus, IL-10 and Tregs may function to inhibit immune-mediated pathology in TB 
patients.
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a symptomatic improvement. CRP and ESR were deter-
mined. Plasma was separated from peripheral blood 
mononuclear cells (PBMCs) at 3000  rpmfor 5  min and 
was stored at −80 °C until use. PBMCs were isolated by 
density centrifugation on with Ficoll, according to the 
manufacturer’s instructions.
Flow cytometric analysis of lymphocyte subtypes
The following monoclonal antibodies were used in the 
present study: FITC-anti-CD4/PE-anti-CD8/Percp-anti-
CD3, FITC-anti-CD4, PE-anti-CD25, APC-anti-
CD127, FITC-anti-CD3/PE-anti-CD56 APC-anti-CD3, 
FITC-anti-CD56 (BD Pharmingen, San Diego, CA, 
USA), PE-anti-IL-17A and PE-anti-IFN-γ (eBioscience, 
ST, USA). Cells were stained according to standard pro-
cedures by incubating the antibodies at 4 °C for 30 min. 
Intracellular cytokine staining was performed by fixing 
and permeabilizing the cells with the Cytofix/Cytop-
erm Fixation/Permeabilization Kit (BD Pharmingen, 
CA, USA) according to the manufacturer’s instructions. 
Flow cytometry was performed on the BD canto II and 
the data was analyzed using BD Diva software (BD, San 
Diego, CA, USA).
Cell culture
A549 cells are an alveolar type-II epithelial cell line, that 
were cultured in DMEM (Gibco, CA, USA), supple-
mented with 100 units/mL penicillin, 100  μg/mL strep-
tomycin, and 10 % fetal bovine serum (FBS) (Gibco, CA) 
at 37  °C, 5  % CO2. Cells were seeded in 96-well tissue 
culture plates, following 60–70  % adherence. 100  ng/
mL recombinant IL-17A (rOPN, R&D, MN, USA) and 
15  μg/mL pulmonary Mycobacterium bovis bacille Cal-
mette–Guerin (BCG, Shanghai Institute of Biological 
Products Co., Ltd, China) were added respectively. Cells 
and supernatants were harvested at 24  h. The superna-
tants were used to determine the concentration of lactate 
dehydrogenase (LDH) according to the manufacturer’s 
instructions (Roche, Mannheim, Germany). An analy-
sis of cellular apoptosis was carried out according to the 
manufacturer’s instructions (BD Pharmingen, San Diego, 
CA, USA).
PBMCs from health volunteers were cultured at 37 °C, 
5 % CO2 in RPMI 1640 (Gibco, CA, USA), supplemented 
with 100  units/mL penicillin, 100  μg/mL streptomycin, 
and 10  % FBS. Cells were incubated with recombinant 
IL-10 (10 μg/mL, Biolegend, CA, USA) and BCG (15 μg/
mL). Golgi inhibitor was added for the last 5  h of the 
incubation. Cells were harvested at 24 h, and intracellular 
cytokine analysis of IL-17A production was conducted 
according to the manufacturer’s instructions.
Cytokines analysis
IL-17A, IL-6, IL-23 and IFN-γ were determined by the 
Luminex enzyme immunoassay (Luminex, TX, USA) 
according to the manufacturer’s protocol (Millipore, Bos-
ton, MA, USA).
ELISPOT assay
According to the manufacturer’s instructions, the IL-17A 
and IFN-γ ELISPOT assays were performed using com-
mercially available kits (eBiosciences, USA). A total of 
2 × 106 PBMCs were cultured with PMA (25 ng/mL) and 
ionomycin (1 ng/mL) in complete RPMI 1640 medium at 
37  °C for 24 h. After stimulation, the positive cells were 
enumerated by an ImmunoSpot S5 Macro Analyzer 
(C.T.L., Shaker Heights, OH, USA), and expressed as the 
numbers of IL-17A and IFN-γ spot-forming units per 
well.
ELISA
ELISA kit for IL-10 (eBioscience, San Diego, CA, USA) 
was used to determine the concentrations of IL-10 
according to the manufacturers’ instructions.
Statistical analyses
Data are presented by box plot or mean ± SD. The sig-
nificance of differences between two groups was deter-
mined using a non-parametric test. A correlation 
analysis was performed using the Pearson’s correlation 
coefficient analysis. A p value of less than 0.05 was con-
sidered to be statistical significance. *p < 0.05. **p < 0.01, 
***p  <  0.001. All analyses were performed using SPSS 
software.
Table 1 Clinical characteristics of patients with pulmonary 
tuberculosis
a HERZ, isoniazid, ethambutol, rifampicin, plus pyrazinamide. Categorical 
variable data are presented as positive/tested (%). Continuous variable data are 
shown as mean ± SD (range)
HC (n = 20) AFB-positive TB 
patients (n = 20)
Age (years) 45 ± 21.9 (22–76) 55 ± 19.8 (18–86)
Sex (m/f ) 12/8 13/7
Radiographic features
Infiltration – 20/20 (100)
Cavitation – 7/20(35)
Effusion – 3/20 (15)
Smear grading
4+ – 5/20 (25)
3+ – 6/20 (30)
2+ – 5/20 (25)
1+ – 4/20 (20)
Resistance – –
Treatment – HREZa 20/20 (100)
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Results
IL-17 level increased in AFB-positive patients 
but decreased after smear conversion
Firstly, we detected plasma cytokines levels in patients 
with AFB-positive pulmonary TB and healthy controls. 
We found that plasma levels of IL-17, IL-6, IL-23 and 
IFN-γ were significantly elevated in the AFB-positive 
group compared to healthy controls (HC) (all p < 0.001) 
(Fig.  1a–d). After the effective treatment, the patients 
achieved AFB-negative status. We found that plasma 
levels of IL-17, IL-6, IL-23 and IFN-γ were remarkably 
decreased in the AFB-negative group in comparison with 
the smear-positive group (all p < 0.001) (Fig. 1a–d). How-
ever, the levels of IL-17, IL-6 and IFN-γ were also high 
in the AFB-negative group compared to healthy controls, 
except the level of IL-23 had no significant difference 
between the two groups.
To further verify the decrease of IL-17 level after smear 
conversion, ELISPOT assays were performed. We found 
that the numbers of IL-17- and IFN-γ-secreting cells were 
increased in the AFB-positive group compared to healthy 
controls (Fig. 1e). In contrast, the numbers of IL-17- and 
IFN-γ-secreting cells were decreased after smear conver-
sion (Fig. 1e).
Comparison of lymphocyte subgroups in the peripheral 
blood between the AFB-positive and AFB-negative groups
IL-17 is a pro-inflammatory cytokine mainly produced by 
Th17 cells [6, 7, 21], a subpopulation of T lymphocytes. 
Firstly, we observed the distribution of T lymphocyte 
populations. There were no significant differences in the 
frequencies of CD3+ T cells, CD4+ T cells and CD8+ T 
cells between the AFB-negative and AFB-positive groups 
(Fig. 2a–c).
Recently, it was reported that the activated NKT-like 
(CD3+CD56+) cells were capable of rapidly producing 
IL-17 [22]. Thus, we further observed the alterations of 
NKT-like cells and found that the percentage of NKT-like 
cells in the AFB-positive group was similar with that in 
the AFB-negative group (Fig. 2d).
NKT-like cells produced significant amounts of IL-17
To further investigate the source of IL-17 in TB patients, 
IL-17-producing cells in NKT-like cells (CD3+CD56+) 
and conventional T cells (CD3+CD56−) were detected. 
We found that the percentage of IL-17-producing cells in 
NKT-like cells was decreased in the AFB-negative group 
in comparison with the AFB-positive group (p = 0.0344) 
(Fig.  3a, b). The frequency of IL-17-producing cells in 
Fig. 1 Elevated IL-17 levels in AFB-positive patients decreased after smear conversion. Plasma levels of a IL-17, b IL-6, c IL-23, and d IFN-γ in the 
AFB-positive group compared to the AFB-negative group were analyzed by ELISA. Data are presented by a box plot. e The expression of IL-17 and 
IFN- secreted by PBMCs from the AFB-positive group and AFB-negative group were determined by ELISPOT assays
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conventional T cells had a decreased trend but there was 
no statistical difference in the AFB-negative compared to 
AFB-positive groups (p = 0.1602) (Fig. 3a, b).
The decreased percentage of IL-17-producing cells 
in NKT-like was consistent with the low expression of 
plasma IL-17 level in TB patients after smear conver-
sion, which suggested that NKT-like cells might also be 
an important source of IL-17, in addition to conventional 
T cells in TB patients.
IL-17 level was correlated to both CRP and ESR
Previous studies had reported that CRP and ESR could 
be considered as severity indicators of pulmonary TB 
[23–26]. To investigate the relationship between IL-17 
levels and the severity of pulmonary TB, the correlation 
between IL-17 level and CRP as well as ESR were con-
ducted. We found that IL-17 level presented a signifi-
cantly positive correlation with CRP level (r  =  0.6030, 
p  <  0.001) (Fig.  4a), and that IL-17 level was also posi-
tively correlated to ESR level (r  =  0.5720, p  <  0.001) 
(Fig.  4b). These data suggested that IL-17 level might 
have some correlation with the severity of pulmonary TB.
IL-17 could aggravate alveolar epithelial cells damage 
after BCG stimulation in vitro
Recent studies have shown that the IL-17 plays an impor-
tant role in initial immune response and is involved in 
immune pathology in MTB infection [2, 9, 10]. Thus, we 
Fig. 2 The frequencies of PBMC subsets from the AFB-positive group compared to the AFB-negative group. The distribution of a CD3+ cells, b 
CD4+ cells, c CD8+ cells, and d NKT-like cells out of the total PBMCs were analyzed, and the percentages of these cells were compared between the 
AFB-positive and AFB-negative groups by flow cytometry analysis
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determined the influence of IL-17 on alveolar epithelial 
cells. We found that alveolar epithelial cells apoptosis was 
increased after IL-17 stimulation and BCG stimulation, 
respectively (Fig.  5a, b). Furthermore, IL-17 stimulation 
combined with BCG induced a higher level of cells apop-
tosis compared to IL-17 stimulation alone (Fig.  5a, b). 
These data indicated that IL-17 might induce alveolar epi-
thelial cells apoptosis during MTB infection (Fig. 5a, b).
LDH is a cytosolic enzyme that is released upon cell 
damage [27], and could be released by alveolar epi-
thelial cells. To further confirm the damage IL-17 on 
alveolar epithelial cells, we examined the level of LDH 
released by alveolar epithelial cells after IL-17 treat-
ment in  vitro. The level of LDH released from alveo-
lar epithelial cells was increased after IL-17 treatment. 
IL-17 combined with BCG could enhance the release 
Fig. 3 Comparison of the frequency of IL-17-producing cells in the peripheral blood between the AFB-positive and AFB-negative groups. a A scat-
terplot and b the frequencies of the IL-17-producing cell in the NKT-like cell and T cell populations from the AFB-positive group compared to the 
AFB-negative group. Data were presented by a box plot. *p < 0.05
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of LDH from alveolar epithelial cells (Fig.  5c). These 
results suggested that IL-17 could induce alveolar epi-
thelial cells damage and aggravate lung injury in MTB 
infection.
IL-17 secretion might be regulated by Treg cell and IL-10 
after MTB infection
Recently, some studies have indicated that Treg cells 
may be an important protective factor in the progression 
Fig. 4 Correlation between the severity of the disease and the IL-17 level. a A Pearson’s correlation coefficient analysis between IL-17 and C-reactive 
protein (CRP) in patients was performed. b Pearson correlation coefficient analysis between IL-17 and erythrocyte sedimentation rate (ESR) in 
patients was performed
Fig. 5 The effect of IL-17 on alveolar epithelial cells. a The scatterplots and b the percentage of apoptosis (early apoptosis Q2 and late apoptosis 
Q4) in alveolar epithelial cells 24 h after stimulation by IL-17 alone, or by IL-17 combined with BCG. c The levels of LDH released by alveolar epithelial 
cells 24 h after stimulation with IL-17 alone or combined with BCG. Data are presented as the mean ± SD. **p < 0.01; ***p < 0.001
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of immune pathological damage by inhibiting Th17 cell 
response in a series of diseases including chronic hepa-
titis B [28, 29] and autoimmune disorders [30, 31]. Treg 
cells could produce amounts of IL-10 [32–34]. In MTB 
infection, Treg cells and IL-10 could also limit the 
immune pathological damage [19, 20, 33]. To investi-
gate the potential mechanism of IL-17 alteration during 
anti-TB treatment, we observed Treg cells distribution 
and IL-10 expression. The percentage of Treg cells was 
remarkably elevated in the AFB-negative group com-
pared to AFB-positive group (p  =  0.0084) (Fig.  6a, 
b). Meanwhile, plasma IL-10 level was significantly 
increased in the AFB-negative group in comparison with 
AFB-positive group (p < 0.001) (Fig. 6c). Furthermore, we 
analyzed the correlation between IL-17 level and IL-10 
level, and found that plasma IL-17 level had a signifi-
cantly negative correlation with IL-10 level (r = −0.7092, 
p < 0.001) (Fig. 6d).
To further illustrate the function of IL-10 on IL-17 
secretion during TB infection, we determined the fre-
quency of IL-17-producing cells in healthy PBMCs after 
BCG stimulation combined with recombinant IL-10. We 
found that the percentages of IL-17-producing cells in 
NKT-like cells and IL-17-producing cells in T cells were 
increased after BCG stimulation (Fig.  6e). The admin-
istration of IL-10 could decrease the frequencies of IL-
17-producing cells in NKT-like cells and IL-17-producing 
cells in T cells induced by BCG stimulation (Fig.  6e). 
These data indicated that Treg cells and IL-10 might 
inhibit the production of IL-17 during anti-TB treatment.
Discussion
Tuberculosis is still a major public health problem in the 
world. Though a series of studies have shown that IFN-γ 
and CD4+ T cells play important roles in controlling both 
bacterial growth and immunopathology during MTB 
infection [2–4, 35, 36], the Th1 cells (primarily CD4+ 
cells producing IFN-γ) alone is not enough to control the 
infection [3, 5]. While previous studies have shown that 
IL-17 is associated with both protection and pathology in 
the context of an MTB infection [2, 9, 10], the changes 
in IL-17 production following anti-TB treatment remains 
unknown.
In this study, we found that plasma IL-17 level was 
increased in AFB-positive patients, but obviously 
decreased after smear conversion. IL-17 is a proinflam-
matory cytokine mainly produced by Th17 lymphocytes, 
which play an immunoregulatory role by producing a 
unique spectrum of pro-inflammatory cytokines IL-17A, 
IL-17F, IL-22, IL-26, and IFN-γ [11]. These cytokines 
could induce the activation and recruitment of neutro-
phils, macrophages, and Th1 lymphocytes into the site 
of infection, which contributed to delimitation of the 
damaged area in the lung tissue, as well as the inhibition 
of MTB growth [37]. In contrast, other studies demon-
strated that IL-17 played an essential role in the forma-
tion of granuloma in  the  lung [17], and was involved in 
pathological damage in the lung by initial neutrophil 
recruitment after MTB infection [18]. In our study, we 
found that IL-17, especially combined BCG, could induce 
alveolar epithelial cells apoptosis and LDH release, which 
indicated that the increase of IL-17 in AFB-positive pul-
monary TB patients might induce lung pathological 
damage.
T cells are considered as an important source of IL-17 
[6, 7, 21]. NKT cells are distinct innate immune T cells 
which play a key role in the pathogenesis of various 
immunomediated liver diseases [38, 39]. In MTB infec-
tion, NKT cells could produce IL-21 to help B cells for 
the production of immunoglobulins [40] and participate 
in the local immune response against MTB through the 
production of IFN-γ and the secretion of cytolytic mol-
ecules [41]. CD3+CD56+ cells are not classical invariant 
NKT cells, but CD3+CD56+ cells are co-expressing T cell 
receptor and NK cell receptors. Recently, it was reported 
that activated NKT-like cells (CD3+CD56+) were capa-
ble of rapidly producing IL-17 [22, 42]. Our previous 
study showed that the percentage of NKT-like cells 
was significantly decreased after telbivudine therapy in 
chronic hepatitis B patients, and that a positive correla-
tion between the frequency of NKT-like cells and serum 
HBV DNA level was observed [22]. In all pulmonary TB 
patients, irrespective of the clinical form (infiltrative pul-
monary TB and disseminated pulmonary TB) and vari-
ant of the MTB infection (drug-sensitive pulmonary TB 
and drug-resistant pulmonary TB), the content of IL-17+ 
NKT-like cell in the peripheral blood was elevated com-
pared to healthy individuals [11]. In our study, we found 
that the frequency of IL-17-producing cells in NKT-like 
cells was significantly decreased in the AFB-negative 
group in comparison with AFB-positive group. These 
data were consistent with the changes of plasma IL-17 
level after anti-TB treatment, and suggested that NKT-
like cells might also be the main source of IL-17, in addi-
tion to conventional T cells in TB patients.
Patients with AFB-positive pulmonary TB are highly 
infectious. Sputum smear conversion is that the growth 
of acid-fast bacilli in the lung is controlled, which is asso-
ciated with a reduction in the rate of treatment failure 
and relapse [43, 44]. In our study, we found that plasma 
IL-17 level and the frequency of IL-17-producing cells 
in NKT-like cells were decreased after anti-TB treat-
ment. Both CRP and ESR are considered as prognostic 
indicators in patients with pulmonary TB [24–26]. In 
our study, we found that the increase of IL-17 was corre-
lated to both CRP and ESR, and could aggravate alveolar 
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Fig. 6 IL-17 secretion might be regulated by Treg cell and IL-10 in MTB infection. a The scatterplots and b the frequencies of Treg cells in PBMCs 
were presented. c Plasma levels of IL-10 in the AFB-positive group compared to AFB-negative group were analyzed by ELISA. Data were presented 
by box plot. **p < 0.01. d Correlation analysis between IL-10 and IL-17 in patients was analyzed. e The frequencies of IL-17-producing cell in NKT-like 
cells and T cells after stimulation with BCG alone or combined with rIL-10 were analyzed by flow cytometry
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epithelial cells damage after BCG stimulation. These data 
indicated that the decrease of plasma IL-17 level and IL-
17-producing cells in NKT-like cells frequency after anti-
TB treatment might be beneficial for patients. However, 
the regulation of IL-17 alteration during treatment is still 
unclear.
Recently, some studies have indicated that Treg cells 
may be an important protective factor in the progression 
of immune pathological damage by inhibiting Th17 cell 
response in a series of diseases, such as chronic hepatitis 
B [28, 29] and autoimmune disorder [30, 31]. Treg cells 
could produce amounts of IL-10 [32–34]. In MTB infec-
tion, Treg cells and IL-10 also could limit the immune 
pathological damage [19, 20]. In our study, we found that 
the percentage of Treg cells was remarkably elevated in 
the AFB-negative group compared to the AFB-positive 
group. This was in opposition to the trend exhibited by 
the frequency of IL-17-producing cells in NKT-like cells. 
Moreover, the plasma IL-17 level had a significantly neg-
ative correlation with IL-10 level. Furthermore, IL-10 
could decrease the percentages of IL-17-producing cells 
in NKT-like cells and IL-17-producing cells in T cells 
induced by BCG. These data indicated that the increase 
of the frequency of Tregs and IL-10 level following TB 
treatment could inhibit the expression of IL-17. This 
effect may function to alleviate the extent of immune 
injury in TB patients.
Conclusions
In summary, we found that IL-17 was increased in AFB-
positive pulmonary TB patients, but obviously substantially 
decreased after treatment following anti-TB treatment. 
Additionally, NKT-like cells might be an important source 
of IL-17, besides in addition to conventional T cells in TB 
patients. IL-17 could was also demonstrated to induce lung 
injury and epithelial apoptosis following MTB infection in 
MTB infection. The secretion of IL-17 may be regulated 
by Treg cells and IL-10 during anti-TB treatment. These 
results suggest that IL-17-producing NKT-like cells may 
play an important role in pulmonary TB patients.
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